Ithaca, NY (March 03, 2015) – Zymtronix has been awarded $747,000 from the National Science Foundation. The two-year award will fund the development of optimized biocatalysis be used in the manufacturing of active pharmaceutical intermediates (API). 

A major challenge for today’s industrial biotechnology companies is to develop new products, processes and services that can yield economic, societal and environmental improvements. Optimized biocatalysis – the use of enzymes for the conversion of chemicals – can simultaneously achieve these three goals. Zymtronix’s technology reduces the cost and quantity of chemicals involved in making drugs. Our solution benefits the industrial sector by improving on existing process efficiencies and margins while limiting adverse environmental impact.

Comments